Treatment Decisions in Non-Small Cell Lung Cancer


In a recent OncLive® Scientific Interchange, Roy S. Herbst, MD, PhD served as the moderator for a discussion on n using immunotherapy (IO) and targeted therapeutics in patients with NSCLC, to discuss factors impacting therapeutic selection and sequencing strategies in NSCLC, and to evaluate and obtain feedback on the evolving landscape of immunotherapy–based regimens in treating the disease.

Related Videos
Corey J. Langer, MD
Roy S. Herbst, MD, PhD
Related Content